The markets have roared higher over the past year, but few stocks have had the kind of run-up that developmental 3-D bioprinting company Organovo Holdings (ONVO) has. Organovo's stock has jumped by more than 125% over the past year, but this company has yet to generate any meaningful revenue, and its bioprinting technology has only caught on with a few partnerships, most recently one with the NIH to print tissue for research purposes.
However, is trouble on the horizon? This week, noted short-selling site Citron Research sent out a warning to investors over Organovo's stock. Among other issues, Citron noted the stock's lack of sell-side coverage and significant institutional ownership in questioning how the stock's jumped so far so fast.
Is Citron on to something with Organovo? In the video below, Motley Fool contributor Dan Carroll tells you what you need to know about the latest news swirling around this hot stock -- and whether or not you can believe in Organovo's stock's rapid rise.
